Reframe Daily: Aspirin helps PI3K-altered colon cancer + what would you do if you have a year to live?

Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible healthtech updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: Low-dose aspirin helped people with a genetic subtype of colon cancer (PI3K-altered) after surgery; a once-daily psoriasis pill (icotrokinra) beat placebo and an approved oral drug in a phase 3 trial; a small implant kept blood pressure steady in people with spinal-cord injury; and an immune drug (antithymocyte globulin) showed dose-based benefit soon after type 1 diabetes starts.

Christin’s note: apologies, I didn’t realize that yesterday’s Reframe Daily never went out! Here it is.. and here’s a video today (with husky voice) about a reflective question I like to ask: “what would you do if you have a year to live?”

Pop in the Discord to chat about health →
https://forms.gle/tN3oabFTsDF21VnS8

Weekly personal shares from Christin here →
http://christin.substack.com/

Good news: A cheap, familiar pill may help a specific group of colon-cancer patients after surgery.

Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer

Market readiness: 🙂🙂🙂🙂🙂 (widely available now; off-label use is feasible while guidelines update in PI3K-altered disease). 

Good news: A once-daily pill cleared psoriasis better than placebo and an approved oral rival in a large trial (head-to-head).

Once-daily oral icotrokinra vs placebo and once-daily oral deucravacitinib in moderate-to-severe plaque psoriasis (ICONIC-TOTAL): phase 3 RCT

Market readiness: 🙂🙂🙂🙂 (late-stage phase 3 success; U.S. filing/review next, not yet approved). 

Good news: An implanted spinal stimulator stabilized blood pressure in people with spinal-cord injury, easing dizzy spells and daily limits.

An implantable system to restore hemodynamic stability after spinal cord injury

Market readiness: 🙂🙂🙂 (human feasibility/early clinical studies; pivotal trial anticipated; not FDA-approved yet). 

Good news: An existing immune therapy showed dose-dependent, disease-modifying promise soon after type 1 diabetes diagnosis.

Antithymocyte globulin as a disease-modifying therapy for new-onset type 1 diabetes: randomized adaptive dose-ranging trial

Market readiness: 🙂🙂🙂 (phase 2 signal; the drug is approved for other uses, but T1D would need phase 3 and a new indication). 

Thank you for taking the time to take care of yourself and your loved ones.